S. Lonial

W. Curran, G. Sica, Melissa Gilbert-Ross, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bortezomib‐containing induction regimens in transplant‐eligible myeloma patients

C. Flowers, S. Lonial, M. Behera, 2013, Cancer.

Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.

S. Lonial, Z. Chen, D. Shin, 2019, The Journal of clinical investigation.

Hsp 90 B enhances MAST 1-mediated cisplatin resistance by protecting MAST 1 from proteosomal degradation

S. Lonial, Z. Chen, D. Shin, 2019 .

The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma

S. Lonial, A. Langston, 2011 .

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.

K. Anderson, H. Einsele, P. Sonneveld, 2009, Blood.

bortezomib- containing regimens cell collection following initial therapy with thalidomide, lenalidomide or Mobilization in myeloma revisited: IMWG consensus perspectives on stem

K. Anderson, H. Einsele, P. Sonneveld, 2009 .

The Importance of Complete Response in Outcomes in Myeloma

S. Lonial, J. Kaufman, A. Nooka, 2009, Cancer Journal.

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

S. Lonial, A. Nooka, C. Gleason, 2013, Biologics : targets & therapy.

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.

K. Anderson, M. Dimopoulos, H. Einsele, 2015, Blood.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Jason J. Z. Liao, H. Goldschmidt, S. Jagannath, 2019, The Lancet. Haematology.

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma

S. Lonial, J. Laubach, P. Richardson, 2016, Expert opinion on biological therapy.

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

A. Palumbo, S. Lonial, J. San-Miguel, 2015, Leukemia.

Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2015, Leukemia & lymphoma.

The White House crusade against ... MGUS?

S. Lonial, 2010, Blood.

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

Nisha S Joseph, M. Dimopoulos, S. Lonial, 2020, Blood Cancer Journal.

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites

S. Lonial, Zhengjia Chen, J. Kaufman, 2018, Cancer.

Induction therapy for newly diagnosed multiple myeloma.

S. Lonial, J. Miguel, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

H. Goldschmidt, S. Lonial, R. Vij, 2012, Leukemia & lymphoma.

Hematopoietic Cell Transplantation for Primary Plasma Cell Leukemia: Results from the Center for International Blood and Marrow Transplant Research

S. Lonial, P. Hari, A. Dispenzieri, 2011, Leukemia.

Presentation and risk stratification--improving prognosis for patients with multiple myeloma.

S. Lonial, 2010, Cancer treatment reviews.

Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

S. Lonial, J. Kaufman, A. Nooka, 2017, Blood.

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

S. Lonial, P. Richardson, P. Voorhees, 2020, Blood Cancer Journal.

Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity

S. Lonial, J. Everly, 2005, Expert opinion on biological therapy.

Immunomodulation: the role of hematopoietic cytokines.

S. Lonial, 2004, Supportive cancer therapy.

Hematopoietic cytokines: when treating the symptoms does not treat the disease.

S. Lonial, 2003, Supportive cancer therapy.

High-risk multiple myeloma: does it still exist?

S. Lonial, S. Tuchman, 2011, Clinical lymphoma, myeloma & leukemia.

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

D. Esseltine, P. Wen, S. Lonial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors

S. Lonial, Shi-Yong Sun, J. Kaufman, 2008, Clinical Cancer Research.

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents

Nisha S Joseph, C. Hofmeister, S. Lonial, 2018, Cancer.

High‐risk Multiple Myeloma: Definition and Management

Nisha S Joseph, S. Lonial, J. Kaufman, 2017, Clinical lymphoma, myeloma & leukemia.

From: 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006, Orlando, FL

J. Armitage, S. Lonial, L. Shivakumar, 2007 .

Phase I/II trial of pralatrexate in patients with chemotherapy-resistant precursor and peripheral T-cell lymphomas

J. Armitage, S. Lonial, L. Shivakumar, 2007 .

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

W. Curran, G. Sica, F. Khuri, 2020, Journal for ImmunoTherapy of Cancer.

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2014, The Lancet. Oncology.

New cancers after autotransplantations for multiple myeloma.

A. Krishnan, S. Lonial, P. Hari, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA polymorphism and risk of multiple myeloma

M. Beksac, S. Lonial, A. Dispenzieri, 2016, Leukemia.

Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice.

S. Lonial, M. Mateos, S. Rajkumar, 2022, The Lancet. Haematology.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2013, Leukemia.

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

Jing Chen, Taro Hitosugi, Jianxin Xie, 2009, Science Signaling.

Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.

Taro Hitosugi, Gary LeRoy, Chuan He, 2012, Cancer cell.

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

R. Neuwirth, S. Lonial, K. Venkatakrishnan, 2010, Cancer Chemotherapy and Pharmacology.

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma

S. Lonial, J. Kaufman, A. Nooka, 2010, Cancer.

Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma.

S. Lonial, J. Kaufman, C. Gleason, 2007 .

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

F. Khuri, S. Lonial, T. Owonikoko, 2020, British Journal of Cancer.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.

S. Jagannath, S. Lonial, R. Vij, 2010 .

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

S. Jagannath, S. Lonial, J. Kaufman, 2008, Leukemia.

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy.

D. Esseltine, P. Wen, K. Anderson, 2005 .

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life.

C. Hofmeister, S. Lonial, J. Kaufman, 2021, Transplantation and cellular therapy.

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Nisha S Joseph, C. Hofmeister, S. Lonial, 2019, Blood Cancer Journal.

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

D. Auclair, R. Fonseca, S. Jagannath, 2017, Clinical lymphoma, myeloma & leukemia.

Neosartorya fischeri: an invasive fungal pathogen in an allogeneic bone marrow transplant patient

S. Lonial, M. Ostrowski, G. Carrum, 1997, Bone Marrow Transplantation.

Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.

S. Lonial, P. Richardson, A. Chanan-Khan, 2007 .

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

K. Anderson, A. Jakubowiak, A. Krishnan, 2007 .

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

S. Jagannath, S. Lonial, P. Richardson, 2017, Clinical Cancer Research.

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2010, Leukemia research.

A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses.

S. Lonial, E. Waller, H. Rosenthal, 2002, Vaccine.

Regulation of alloimmune responses by dendritic cell subsets.

S. Lonial, C. Torre, E. Waller, 2008, Experimental hematology.

The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway

F. Khuri, S. Lonial, Shi-Yong Sun, 2007, Molecular Cancer Therapeutics.

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2015, British journal of haematology.

Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation.

S. Lonial, M. Boyer, E. Waller, 2001, Blood.

Review of peripheral neuropathy in plasma cell disorders

S. Lonial, Jeannine Silberman, 2008, Hematological oncology.

Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.

S. Lonial, G. Qian, Shuo Zhang, 2018, Cancer letters.

The Tao of myeloma.

S. Lonial, J. Kaufman, L. Boise, 2014, Blood.

Advances in current treatment for patients with newly diagnosed multiple myeloma.

S. Lonial, 2013, Leukemia supplements.

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma

M. Dimopoulos, S. Lonial, R. Foà, 2012, International Journal of Hematology.

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

R. Neuwirth, D. Esseltine, H. Goldschmidt, 2008, Leukemia.

Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.

S. Lonial, J. Kaufman, S. P. Gladney, 2008, Clinical lymphoma & myeloma.

Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma

P. Sonneveld, S. Lonial, P. Richardson, 2007, British journal of haematology.

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

Joseph D Tariman, S. Lonial, N. Munshi, 2007, Blood.

DC 2 Effect on Survival Following Allogeneic Bone Marrow Transplantation

S. Lonial, E. Waller, 2017 .

Results of a clinical phase I dose-escalation study of cytarabinein combination with fixed-dose vinorelbine, paclitaxel, etoposideand cisplatin for the treatment of relapsed/refractory lymphoma

C. Flowers, S. Lonial, E. Waller, 2006, Leukemia & lymphoma.

Smoldering multiple myeloma current treatment algorithms

S. Lonial, Shaji K. Kumar, S. Rajkumar, 2022, Blood Cancer Journal.

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.

A. Krishnan, S. Lonial, R. Vij, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors

G. Sica, F. Khuri, S. Lonial, 2020, Clinical Cancer Research.

Plerixafor in combination with granulocyte–colony‐stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial

C. Flowers, S. Lonial, J. Kaufman, 2015, Transfusion.

Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.

C. Flowers, S. Lonial, J. Kaufman, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Maintenance therapy in lymphoma.

C. Flowers, S. Lonial, J. Kaufman, 2007, Clinical lymphoma & myeloma.

Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells

Kenneth J. Smith, C. Flowers, S. Lonial, 2007, Transfusion.

Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia

S. Lonial, Zhengjia Chen, H. Khoury, 2012, Cancer.

150: A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration

C. Flowers, S. Lonial, C. Torre, 2007 .

A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma.

C. Flowers, S. Lonial, C. Torre, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

A. Krishnan, S. Lonial, P. Richardson, 2006 .

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

S. Jagannath, S. Lonial, N. Munshi, 2022, The New England journal of medicine.

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

S. Lonial, Zhengjia Chen, J. Kaufman, 2015, Cancer.

Natural history of multiple myeloma patients refractory to venetoclax: A single center experience

Nisha S Joseph, C. Hofmeister, S. Lonial, 2020, American journal of hematology.

Effectiveness and cost analysis of “just‐in‐time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics

C. Flowers, S. Lonial, J. Kaufman, 2011, Transfusion.

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

H. Goldschmidt, H. Einsele, S. Lonial, 2021, The New England journal of medicine.

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

S. Lonial, S. Iida, T. Plesner, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?

C. Flowers, S. Lonial, Zhengjia Chen, 2016, Clinical lymphoma, myeloma & leukemia.

AKT inhibitors in multiple myeloma

S. Lonial, R. Harvey, 2013 .

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

S. Lonial, J. Kaufman, E. Waller, 2011, Leukemia.

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.

S. Jagannath, S. Lonial, P. Richardson, 2022, The Lancet. Haematology.

Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.

A. Jakubowiak, A. Krishnan, S. Lonial, 2021, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.

M. Beksac, M. Dimopoulos, S. Lonial, 2020, The Lancet. Oncology.

Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

A. Jakubowiak, S. Lonial, A. Oriol, 2019, Blood.

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

J. Fay, A. Krishnan, S. Lonial, 2017, Blood.

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Bart Barlogie, Monika Engelhardt, Niels Abildgaard, 2017, The Lancet. Oncology.

Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.

S. Lonial, R. Ahmed, J. Kaufman, 2018, Journal of oncology practice.

Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius

S. Lonial, P. Richardson, A. Belch, 2017 .

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in

D. Esseltine, S. Jagannath, A. Jakubowiak, 2012 .

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

R. Neuwirth, H. Goldschmidt, P. Sonneveld, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

D. Auclair, A. Krishnan, S. Lonial, 2017, Leukemia.

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

D. Auclair, A. Krishnan, S. Lonial, 2017, Leukemia.

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

D. Auclair, A. Krishnan, S. Lonial, 2017, Leukemia.

Clinical ef ﬁ cacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

S. Lonial, P. Richardson, T. Plesner, 2016 .

Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

G. Mulligan, A. Jakubowiak, S. Lonial, 2009 .

Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent

H. Einsele, S. Lonial, P. Richardson, 2017, Expert review of hematology.

How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.

C. Hofmeister, S. Lonial, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

S. Jagannath, A. Jakubowiak, S. Lonial, 2015, The Lancet. Haematology.

Reconstructing immunity after allogeneic transplantation

S. Lonial, E. Waller, M. S. Hossain, 2004, Immunologic research.

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009 .

A phase 2 study of single-agent carﬁlzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Rare myelomas: sometimes when you hear hooves, it's a zebra...

S. Lonial, S. Gentili, 2013, Oncology.

Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study

J. Carpten, J. Fay, S. Jewell, 2015 .

Interim Analysis of the Mmrf Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression

J. Carpten, S. Jewell, D. Rohrer, 2014 .

Novel combination approaches for myeloma.

S. Lonial, A. Nooka, 2015, Hematology. American Society of Hematology. Education Program.

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

S. Lonial, J. Kaufman, A. Nooka, 2014, Leukemia.

Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma.

S. Lonial, 2013, Leukemia supplements.

Is Subcutaneous Bortezomib Ready for Prime Time?

S. Lonial, 2011, Current hematologic malignancy reports.

Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)

K. Anderson, A. Krishnan, S. Lonial, 2007 .

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

M. Kaminski, D. Esseltine, K. Griffith, 2011, Blood.

Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

S. Jagannath, S. Lonial, R. Vij, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Options for Relapsed and Refractory Multiple Myeloma

S. Lonial, P. Richardson, C. Mitsiades, 2011, Clinical Cancer Research.

Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.

M. Dimopoulos, S. Lonial, D. Weber, 2009 .

Risky business in myeloma.

S. Lonial, 2009, Blood.

Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM).

S. Lonial, J. S. San Miguel, M. Mateos, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

K. Anderson, A. Jakubowiak, A. Krishnan, 2006 .

Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT)

A. Krishnan, S. Lonial, P. Hari, 2012 .

Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation

S. Lonial, M. Boyer, E. Waller, 2001 .

Investigation of Mechanisms of Response in Multiple Myeloma Via Bayesian Causal Inference: An Early Analysis of the Commpass Study Data

B. Hayete, D. Auclair, J. Keats, 2015 .

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.

F. Khuri, S. Lonial, Shi-Yong Sun, 2007, Cancer research.

NSCLC Cells Up-Regulation of c-FLIP and Survivin Expression in Human Enhancement of TRAIL-Induced Apoptosis Despite DR 5 Expression Leading to Induction of Apoptosis and The Proteasome Inhibitor PS-341 ( Bortezomib ) UpRegulates

F. Khuri, S. Lonial, Shi-Yong Sun, 2007 .

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma

S. Lonial, A. Nooka, L. Boise, 2013 .

Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

S. Jagannath, A. Jakubowiak, S. Lonial, 2009 .

Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.

M. Dimopoulos, S. Lonial, R. Orlowski, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM)

B. Barlogie, G. Morgan, A. Palumbo, 2011 .

Novel drug combinations for the management of relapsed/refractory multiple myeloma.

S. Lonial, S. Usmani, 2014, Clinical lymphoma, myeloma & leukemia.

A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

H. Goldschmidt, S. Lonial, R. Vij, 2008 .

Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.

S. Lonial, A. Nooka, C. Gleason, 2018, Future oncology.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Blood.

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.

A. Krishnan, S. Lonial, J. Miguel, 2022, The Lancet. Haematology.

High Dose Chemotherapy Without Hematopoietic Cell Support for the Treatment of Refractory Lymphoma

S. Lonial, E. Waller, A. Yeager, 2000, Leukemia & lymphoma.

Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial

Linda Z Sun, H. Goldschmidt, M. Dimopoulos, 2011 .

Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.

C. Flowers, S. Lonial, A. Nooka, 2011, Clinical lymphoma, myeloma & leukemia.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.

S. Lonial, J. Laubach, P. Richardson, 2020, The Lancet. Haematology.

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.

M. Beksac, M. Dimopoulos, H. Einsele, 2016, Blood.

"A fortuitous combination of circumstances".

S. Lonial, 2013, Blood.

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients

S. Lonial, J. Kaufman, A. Nooka, 2019, Cancer.

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma

S. Lonial, B. Barwick, A. Nooka, 2022, Science advances.

Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.

S. Lonial, M. Boyer, E. Waller, 1999, Blood.

assessment Eliminating the complete response penalty from myeloma response

S. Lonial, M. Gertz, 2011 .

Eliminating the complete response penalty from myeloma response assessment.

S. Lonial, M. Gertz, 2008, Blood.

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

M. Dimopoulos, J. San Miguel, S. Jagannath, 2011, Blood.

Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.

S. Lonial, A. Oriol, N. Lavi, 2020, Clinical lymphoma, myeloma & leukemia.

The Role of Early Intervention in High-Risk Smoldering Myeloma.

S. Lonial, M. Dhodapkar, Nisha S. Joseph, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor

S. Lonial, Y. Tai, K. Anderson, 2021, Clinical pharmacology : advances and applications.

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

H. Goldschmidt, U. Mellqvist, M. Dimopoulos, 2021, The Lancet. Oncology.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

S. Lonial, S. Trudel, P. Richardson, 2019, The Lancet. Oncology.

Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34+ enriched hematopoietic progenitor cells from partially mismatched related donors

S. Lonial, I. Redei, E. Hamilton, 2002, Bone Marrow Transplantation.

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

P. Parren, S. Lonial, P. Richardson, 2019, British journal of haematology.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

J. Leonard, S. de Vos, R. Fisher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hematologic Profiles in the Phase 3 APEX Trial.

H. Goldschmidt, P. Sonneveld, S. Lonial, 2005 .

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Jessica Katz, Hermann Einsele, Paul Richardson, 2015, The New England journal of medicine.

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.

H. Goldschmidt, M. Dimopoulos, S. Lonial, 2022, The Lancet. Haematology.

Antibody treatment in multiple myeloma.

S. Lonial, C. Johnson, Kathryn T. Maples, 2021, Clinical advances in hematology & oncology : H&O.

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study

J. Manola, S. Lonial, A. Dueck, 2018, Blood Cancer Journal.

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.

S. Lonial, T. Plesner, T. Casneuf, 2017, Blood advances.

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

D. Esseltine, H. Einsele, S. Lonial, 2017, British journal of haematology.

Death by a thousand cuts: the slow demise of chemotherapy

S. Lonial, A. Nooka, 2016, Cancer.

Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38

S. Lonial, 2016, Cancer journal.

Treatment of MM: Upcoming Novel Therapies.

S. Lonial, 2016, Cancer treatment and research.

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, S. Lonial, 2014 .

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

S. Lonial, S. Iida, T. Plesner, 2018, Blood.

Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.

A. Jakubowiak, S. Lonial, A. Chari, 2017 .

Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2018, Blood.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, S. Lonial, 2012, Clinical lymphoma, myeloma & leukemia.

Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study

Winnie S. Liang, J. Carpten, J. Fay, 2016 .

Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells

C. Flowers, S. Lonial, J. Kaufman, 2013 .

Management of treatment-emergent peripheral neuropathy in multiple myeloma

P. Wen, G. Morgan, M. Dimopoulos, 2012, Leukemia.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Michael Wang, Michael L. Wang, S. Lonial, 2007, The New England journal of medicine.

Clinical uses of GM-CSF, a critical appraisal and update

S. Lonial, M. Arellano, 2008, Biologics : targets & therapy.

A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.

S. Lonial, C. Torre, E. Waller, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Larger numbers of CD 4 bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation

S. Lonial, M. Boyer, E. Waller, 2001 .

An expanded universe of cancer targets

Hanlee P. Ji, Michael T. McManus, Joshua M. Dempster, 2021, Cell.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

S. Lonial, P. Richardson, S. Coutre, 2013, Blood.

Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.

S. Stowell, S. Lonial, A. Nooka, 2017, Blood.

Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation.

S. Lonial, A. Caliendo, E. Waller, 2002, Blood.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

H. Goldschmidt, H. Einsele, S. Lonial, 2019, The Lancet. Oncology.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2019, The New England journal of medicine.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019, JCI insight.

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019 .

Current strategies for treatment of relapsed/refractory multiple myeloma

A. Jakubowiak, S. Lonial, J. Laubach, 2014, Expert review of hematology.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Bin Li, Matthew Schu, R. Neuwirth, 2014, Blood.

Association of response endpoints with survival outcomes in multiple myeloma

S. Lonial, K. Anderson, K. Anderson, 2013, Leukemia.

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

H. Goldschmidt, H. Einsele, A. Palumbo, 2016, Blood.

Panobinostat for the treatment of multiple myeloma

S. Lonial, P. Neri, Sagar Lonial, 2012, Expert opinion on investigational drugs.

Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation

S. Lonial, S. Ramalingam, M. Behera, 2016, Cancer.

Daratumumab in multiple myeloma

C. Hofmeister, S. Lonial, M. Dhodapkar, 2019, Cancer.

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

G. Morgan, S. Lonial, N. Munshi, 2019, Clinical lymphoma, myeloma & leukemia.

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

Y. Asmann, D. Auclair, J. Keats, 2017, Blood Cancer Journal.

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

M. Dimopoulos, S. Lonial, J. Laubach, 2015, Expert review of anticancer therapy.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Pingping Qu, Fadi Towfic, Konstantinos Mavrommatis, 2018, Leukemia.

Comprehensive Identification of Fusion Transcripts in Multiple Myeloma: An Mmrf Commpass Analysis

D. Auclair, J. Keats, S. Lonial, 2017 .

Treatment options for relapsed and refractory multiple myeloma.

M. Dimopoulos, S. Lonial, A. Nooka, 2015, Blood.

MULTIPLE MYELOMA: FROM THE BENCH TO BEDSIDE Treatment options for relapsed and refractory multiple myeloma

M. Dimopoulos, S. Lonial, A. Nooka, 2015 .

Series MULTIPLE MYELOMA : FROM THE BENCH TO BEDSIDE Treatment options for relapsed and refractory multiple myeloma

M. Dimopoulos, S. Lonial, A. Nooka, 2015 .

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, The Lancet. Oncology.

SECOND TRANSPLANTS FOR MULTIPLE MYELOMA RELAPSING AFTER A PRIOR AUTOTRANSPLANT – REDUCED INTENSITY ALLOGENEIC VERSUS AUTOLOGOUS TRANSPLANTATION

A. Krishnan, S. Lonial, P. Hari, 2013, Bone Marrow Transplantation.

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis.

A. Krishnan, S. Lonial, R. Vij, 2011, Blood.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

B. Barlogie, G. Morgan, M. Dimopoulos, 2009, Leukemia.

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

S. Lonial, J. Kaufman, A. Nooka, 2015, Leukemia.

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma

J. Dudley, B. Barlogie, D. Auclair, 2018, Leukemia.

Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice

S. Lonial, R. Vij, H. Nahi, 2016, American journal of hematology.

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.

M. Dimopoulos, H. Einsele, S. Lonial, 2016, The Lancet. Haematology.

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

G. Mulligan, D. Esseltine, P. Sonneveld, 2012, Blood.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

H. Goldschmidt, G. Morgan, H. Einsele, 2018, Blood.

1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma

Pingping Qu, Fadi Towfic, Konstantinos Mavrommatis, 2018 .

When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response

S. Lonial, L. Boise, Shardule P. Shah, 2015, Molecular Cancer Research.

Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex.

B. Garcia, Erwin G. Van Meir, F. Khuri, 2014, Molecular cell.

A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

B. Tunquist, S. Lonial, R. Orlowski, 2017, Cancer.

Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma

S. Lonial, A. Nooka, 2019, Cancer journal.

Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma

J. Keats, C. Hofmeister, S. Lonial, 2021, Clinical Cancer Research.

FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.

D. Fabbro, Michael S. Cohen, J. Taunton, 2006, Cancer cell.

Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.

C. Brennan, S. Lonial, J. Chen, 2019, Cancer discovery.

Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.

F. Khuri, S. Lonial, Xu Wang, 2011, Molecular cell.

Impact of concurrent gabapentin or pregabalin with high‐dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant

C. Hofmeister, S. Lonial, J. Kaufman, 2022, Pharmacotherapy.

Academic, Foundation, and Industry Collaboration in Finding New Therapies

S. Lonial, G. Nepom, Bonnie W. Ramsey, 2017, The New England journal of medicine.

Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.

F. Khuri, S. Lonial, Xiaoyun Wu, 2009, Cancer research.

Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation

F. Khuri, P. Jin, S. Lonial, 2013, Nature Communications.

Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD+ Redox Homeostasis in Cancer Cells

F. Khuri, S. Lonial, T. Boggon, 2011, Molecular and Cellular Biology.

PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.

S. Lonial, R. Harvey, R. Harvey, 2007, Future oncology.

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth

S. Lonial, Jiusheng Deng, J. Kaufman, 2016, Oncotarget.

Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

F. Khuri, S. Lonial, O. Abdel-Wahab, 2017, Cell metabolism.

6-phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumor growth by inhibiting LKB1-AMPK signaling

Jing Chen, Taro Hitosugi, Jianxin Xie, 2014, Nature Cell Biology.

Breakthroughs in the Management of Multiple Myeloma

S. Lonial, Leonard T. Jr Heffher, 2012, Drugs.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Neeraj Gupta, Eileen Liao, Parameswaran Hari, 2014, The Lancet. Oncology.

Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.

S. Lonial, E. Waller, A. Langston, 2004, Blood cells, molecules & diseases.

MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma

S. Lonial, Xiaodong Cheng, Xing Zhang, 2016, Nucleic acids research.

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

G. Morgan, M. Dimopoulos, A. Palumbo, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis

S. Lonial, M. Behera, J. Kaufman, 2011 .

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma

S. Lonial, B. Barwick, M. Rupji, 2020, Nature Communications.

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

S. Lonial, A. Nooka, L. Boise, 2015, Oncogene.

Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.

S. Lonial, M. Boyer, E. Waller, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Systematic discovery of mutation-directed neo-protein-protein interactions in cancer

G. Mills, F. Khuri, S. Lonial, 2021, Cell.

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Trevor J Pugh, T. Pugh, D. Auclair, 2021, Clinical Cancer Research.

γ-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A.

Christian M. Metallo, R. Deberardinis, S. Lonial, 2019, Molecular cell.

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010, Blood.

The future of drug development and therapy in myeloma.

S. Lonial, L. Boise, 2013, Seminars in oncology.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

D. Esseltine, H. Goldschmidt, P. Wen, 2009, British journal of haematology.

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

A. Krishnan, S. Lonial, P. Richardson, 2011, British journal of haematology.

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

A. Chinnaiyan, D. Auclair, P. L. Bergsagel, 2022, Nature Communications.

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes

S. Lonial, J. Laubach, P. Richardson, 2016, Expert review of clinical pharmacology.

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

M Boccadoro, B. Barlogie, G. Morgan, 2009, Leukemia.

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

S. Lonial, P. Tassone, P. Neri, 2010, Blood.

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models

A. Marcus, F. Khuri, S. Lonial, 2019, PloS one.

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

S. Lonial, P. Richardson, Shaji K. Kumar, 2020, The Lancet. Oncology.

Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation

J. Taunton, S. Lonial, T. Boggon, 2009, Molecular and Cellular Biology.

Safety and survival outcomes for bloodless transplantation in patients with myeloma

C. Flowers, S. Lonial, J. Kaufman, 2018, Cancer.

Older patients with myeloma derive similar benefit from autologous transplantation.

A. Krishnan, S. Lonial, P. Hari, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: res

C. Flowers, S. Lonial, C. Torre, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation.

S. Lonial, E. Waller, A. Langston, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature

S. Lonial, J. Holden, C. Lewis, 1999, Bone Marrow Transplantation.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip

B. Barlogie, M. Dimopoulos, H. Einsele, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Changes in the pattern of TCR Vβ repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans

S. Lonial, E. Waller, C. Bomberger, 2001, British journal of haematology.

Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors

C. Flowers, S. Lonial, J. Kaufman, 2014, Bone Marrow Transplantation.

Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.

C. Flowers, S. Lonial, J. Kaufman, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma

J. Vose, C. Flowers, S. Lonial, 2013, Transfusion.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

J. Witte, M. Lieber, G. Colditz, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

S. Jagannath, S. Lonial, D. Siegel, 2013, Haematologica.

Salvage second hematopoietic cell transplantation in myeloma.

J. Vose, A. Krishnan, S. Lonial, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of acute and chronic graft-versus-host disease on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma

S. Lonial, P. Hari, A. Dispenzieri, 2011, Bone Marrow Transplantation.

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience

C. Hofmeister, S. Lonial, M. Dhodapkar, 2023, Blood Cancer Journal.

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

G. Mulligan, S. Tirrell, A. Jakubowiak, 2015, Clinical Cancer Research.

Safety of proteasome inhibitors for treatment of multiple myeloma

S. Lonial, K. S. Shah, D. Schlafer, 2016, Expert opinion on drug safety.

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

S. Lonial, R. Hájek, A. Di Bacco, 2018, Haematologica.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

J. Witte, G. Colditz, A. Olshan, 2020, Blood advances.

Characteristics and outcomes of diffuse large B‐cell lymphoma presenting in leukaemic phase

D. Weisenburger, J. Armitage, M. Bast, 2012, British journal of haematology.

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma

S. Lonial, B. Barwick, A. Nooka, 2022, Haematologica.

Beta adrenergic signaling regulates HSPC commitment and therapy sensitivity in multiple myeloma.

S. Lonial, B. Barwick, A. Nooka, 2022, Haematologica.

Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2021, Blood cancer discovery.

Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation and MyD88-mutant progenitors precede malignancy in Waldenstrom macroglobulinemia

C. Hofmeister, S. Lonial, M. Dhodapkar, 2021 .

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

D. Auclair, J. Keats, C. Hofmeister, 2019, Nature Communications.

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Michele Cavo, Hermann Einsele, Philippe Moreau, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

A. Jakubowiak, A. Krishnan, S. Lonial, 2016, The Lancet.

Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation*

F. Khuri, S. Lonial, Shi-Yong Sun, 2010, Journal of Biological Chemistry.

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

S. Lonial, R. Kurzrock, H. Borghaei, 2010, Journal of Clinical Oncology.

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

S. Lonial, G. Vanhoof, H. Ceulemans, 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Syddansk Universitet High-Parameter Mass Cytometry Evaluation of Relapsed / Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

S. Lonial, G. Vanhoof, H. Ceulemans, 2019 .

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

Integration of Novel Agents into the Care of Patients with Multiple Myeloma

S. Lonial, R. Orlowski, 2016, Clinical Cancer Research.

Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.

S. Jagannath, S. Lonial, Shaji K. Kumar, 2014, Clinical lymphoma, myeloma & leukemia.

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

J. Shah, U. Mellqvist, M. Dimopoulos, 2014, Leukemia.

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

M. Dimopoulos, S. Lonial, P. Richardson, 2018, Cancer.

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

C. Hofmeister, S. Lonial, D. Siegel, 2017, Leukemia.

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

C. Hofmeister, S. Lonial, J. Laubach, 2015 .

Relapsed multiple myeloma.

S. Lonial, 2010, Hematology. American Society of Hematology. Education Program.

Sequential or combination therapy for multiple myeloma

S. Lonial, A. Nooka, 2012, Expert review of hematology.

When “the same” is really “different”

S. Lonial, 2006 .

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).

S. Lonial, H. Burris, D. Reece, 2006 .

Safety and Efficacy of Bortezomib in Multiple Myeloma Patients with Renal Failure Requiring Dialysis.

S. Jagannath, S. Lonial, S. Singhal, 2005 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

J. Keats, C. Hofmeister, S. Lonial, 2021, Blood.

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

Jing Chen, Fadlo R Khuri, F. Khuri, 2005, Blood.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

M. Dimopoulos, H. Einsele, P. Sonneveld, 2011, Blood.

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

P. Sonneveld, S. Lonial, J. Zonder, 2019, Journal of Clinical Oncology.

A Molecular Analysis of Cereblon-Related Immunomodulatory Drug Resistance in Commpass Multiple Myeloma Patients

D. Auclair, J. Keats, S. Lonial, 2017 .

Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial

D. Auclair, J. Keats, S. Lonial, 2016 .

Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.

C. Flowers, S. Lonial, E. Waller, 2015, Clinical lymphoma, myeloma & leukemia.

Monoclonal antibodies in the treatment of multiple myeloma

A. Jakubowiak, S. Lonial, P. Richardson, 2011, British journal of haematology.

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

D. Esseltine, P. Sonneveld, A. Jakubowiak, 2008, British journal of haematology.

The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

F. Khuri, S. Lonial, O. Abdel-Wahab, 2018, Molecular cell.

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.

M. Dimopoulos, S. Lonial, P. Richardson, 2022, Clinical lymphoma, myeloma & leukemia.

Supportive therapies in multiple myeloma.

S. Lonial, A. Nooka, C. Gleason, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

S. Lonial, J. Cavenagh, 2009, British journal of haematology.

Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma.

S. Lonial, G. Reddy, T. Mughal, 2006, Supportive cancer therapy.

ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma.

H. Einsele, S. Lonial, M. Mohty, 2022, Transplantation and cellular therapy.

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia

S. Lonial, A. Chanan-Khan, J. Kowalski, 2015, Oncogene.

Proteasome Inhibition: Novel Therapy for Multiple Myeloma

S. Lonial, J. Kaufman, 2006, Oncology Research and Treatment.

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

S. Jagannath, S. Lonial, R. Kurzrock, 2013, Clinical Cancer Research.

Ixazomib for the treatment of multiple myeloma

S. Lonial, J. Laubach, P. Richardson, 2018, Expert opinion on pharmacotherapy.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

A. Hui, S. Lonial, P. Richardson, 2011 .

The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.

F. Khuri, S. Lonial, Shi-Yong Sun, 2007, Cancer research.

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

S. Lonial, R. Parikh, 2023, CA: a cancer journal for clinicians.

Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study

C. Flowers, S. Lonial, A. Nooka, 2017, Infection Control & Hospital Epidemiology.

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

C. Hofmeister, S. Lonial, B. Barwick, 2020, Blood Cancer Journal.

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

S. Jagannath, S. Lonial, D. Siegel, 2020 .

Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)

Michael L. Wang, S. Lonial, N. Raje, 2014 .

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

A. Jakubowiak, A. Krishnan, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Journal of Clinical Oncology.

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

S. Lonial, S. Trudel, N. Callander, 2021, Cancer.

Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting

S. Lonial, Christopher D. Scharer, I. Sanz, 2021, Life Science Alliance.

Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.

S. Lonial, P. Richardson, J. Kaufman, 2013, Clinical lymphoma, myeloma & leukemia.

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

F. Khuri, S. Lonial, Xu Wang, 2018, Cancer cell.

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma

S. Lonial, E. Waller, A. Langston, 2006, Cancer.

Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data

S. Lonial, J. Kaufman, A. Nooka, 2013 .

Multiple Myeloma: State of the Art: 075‐MM‐01

S. Lonial, 2017 .

Autologous hematopoietic transplant in multiple myeloma

S. Lonial, A. Nooka, Nisha S. Joseph, 2017 .

Is Maintenance Therapy for Everyone?

S. Lonial, A. Nooka, 2016, Clinical lymphoma, myeloma & leukemia.

High-risk myeloma: when to transplant-or not.

C. Hofmeister, S. Lonial, F. Cavallo, 2014, Seminars in oncology.

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.

A. Krishnan, S. Lonial, P. Hari, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

D. Esseltine, P. Sonneveld, S. Lonial, 2013 .

Multiple myeloma: the role of transplant and novel treatment strategies.

S. Lonial, J. Kaufman, 2004, Seminars in oncology.

autologous stem cell transplantation treatment of multiple myeloma patients who are candidates for International Myeloma Working Group consensus approach to the

M. Dimopoulos, H. Einsele, A. Palumbo, 2012 .

Improving Induction Therapy in Multiple Myeloma

S. Lonial, A. Nooka, C. Gleason, 2010, Current hematologic malignancy reports.

Designing risk-adapted therapy for multiple myeloma: the Mayo perspective.

S. Lonial, 2007, Mayo Clinic proceedings.

Signal Transduction and Myeloma: New Targets, New Hope

S. Lonial, J. Simons, E. Waller, 2003, Cancer biology & therapy.

Novel treatment approaches for patients with relapsed and refractory multiple myeloma

S. Lonial, R. Sinha, 2006, Current treatment options in oncology.

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

S. Lonial, M. Dhodapkar, Robert A Emmons, 2019, Journal of Clinical Oncology.

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

F. Zhan, S. Jagannath, A. Jakubowiak, 2011, European journal of haematology.

Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.

S. Lonial, J. Laubach, P. Richardson, 2020, Clinical lymphoma, myeloma & leukemia.

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

S. Jagannath, S. Lonial, T. Zimmerman, 2019, Clinical lymphoma, myeloma & leukemia.

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

S. Lonial, J. Laubach, P. Richardson, 2019, Leukemia.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

A. Jakubowiak, S. Lonial, J. Kaufman, 2019, Blood Cancer Journal.

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

S. Jagannath, S. Lonial, D. Siegel, 2014 .

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Racial differences in the incidence and outcomes for patients with hematological malignancies.

C. Flowers, S. Lonial, O. Brawley, 2007, Current problems in cancer.

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

S. Jagannath, A. Krishnan, S. Lonial, 2018, Cancer.

Is there still a role for stem cell transplantation in multiple myeloma?

S. Lonial, R. Mina, 2019, Cancer.

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study

Mourad Tighiouart, Christopher R Flowers, R Donald Harvey, 2010, Clinical Cancer Research.

CHALLENGES IN THE MANAGEMENT OF HIGH-RISK MULTIPLE MYELOMA

H. Einsele, P. Sonneveld, D. Auclair, 2023 .

EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit.

S. Lonial, A. Nooka, 2022, Clinical lymphoma, myeloma & leukemia.

“I took the road less traveled, and that has made all the difference”: Making a case for high‐dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma

S. Lonial, A. Nooka, Nisha S. Joseph, 2021, Cancer.

Registering a CD38 antibody upfront for multiple myeloma

C. Hofmeister, S. Lonial, J. Kaufman, 2019, The Lancet.

Novel treatment approaches for patients with multiple myeloma.

S. Lonial, J. Kaufman, R. Sinha, 2006, Clinical lymphoma & myeloma.

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

Wei Chen, G. Morgan, M. Dimopoulos, 2009, Leukemia.

Maintenance therapy in multiple myeloma

S. Lonial, J. Kaufman, R. Mihelic, 2007, Leukemia.

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

S. Lonial, P. Richardson, T. Plesner, 2017, Clinical Pharmacokinetics.

Multiple Myeloma : 2007-2008

A. Jakubowiak, S. Lonial, P. Richardson, 2008 .

Practical considerations for multiple myeloma: an overview of recent data and current options.

S. Lonial, 2008, Clinical lymphoma & myeloma.

Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis

S. Lonial, S. Rajkumar, P. Greipp, 2011 .

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

J. Rossi, S. Jagannath, A. Jakubowiak, 2011 .

Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study.

J. Rossi, S. Jagannath, A. Jakubowiak, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide (LEN) Therapy In Combination with Dexamethasone (DEX) Is Associated with a Low Incidence of Viral Infections

M. Dimopoulos, S. Lonial, R. Baz, 2010 .

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

A. Jakubowiak, A. Krishnan, S. Lonial, 2017 .

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

S. Lonial, P. Richardson, Shaji K. Kumar, 2021, Blood.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma

S. Lonial, P. Neri, N. Bahlis, 2016, Clinical Cancer Research.

Myeloma Is Not a Single Disease.

S. Lonial, A. Nooka, 2016, Journal of oncology practice.

Novel Combination Treatments in Multiple Myeloma.

S. Lonial, A. Nooka, 2016, Oncology.

The era of combination therapy in myeloma.

S. Lonial, J. Kaufman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010 .

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

A. Jakubowiak, S. Lonial, P. Thulasi, 2020, Ophthalmology and Therapy.

Disparities in multiple myeloma among African Americans.

S. Lonial, M. Bhutani, J. Mikhael, 2022, Journal of the National Medical Association.

Multiple Myeloma - a New Era of Treatment Strategies

G. Tonon, S. Lonial, D. Ribatti, 2012 .

New Targets and New Agents in High-Risk Multiple Myeloma.

S. Lonial, A. Nooka, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Multiple myeloma: novel approaches for relapsed disease.

S. Lonial, 2007, Clinical lymphoma & myeloma.

Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles

Winnie S. Liang, J. Carpten, S. Jewell, 2013 .

DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling

S. Lonial, K. Magliocca, Sumin Kang, 2020, Clinical Cancer Research.

Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.

M. Dimopoulos, H. Einsele, S. Lonial, 2015 .

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

M. Dimopoulos, H. Einsele, S. Lonial, 2014 .

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

S. Lonial, P. Richardson, S. Coutre, 2013 .

Retrotransposons facilitate the tissue-specific horizontal transfer of circulating tumor DNA between human cells

I. Lossos, S. Lonial, B. Vardarajan, 2022, bioRxiv.

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial

S. Jagannath, S. Lonial, P. Richardson, 2021, Blood.

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

P. Sonneveld, S. Jagannath, S. Lonial, 2020 .

Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

S. Lonial, S. Trudel, P. Richardson, 2020 .

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

S. Lonial, S. Trudel, P. Richardson, 2020 .

Patient‐reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double‐blind, placebo‐controlled PANORAMA‐1 trial

S. Lonial, P. Richardson, S. Acharyya, 2018, British journal of haematology.

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma

S. Lonial, B. Barwick, M. Rupji, 2020, Nature Communications.

Putting the E (evidence) in a new Era for myeloma

S. Lonial, J. Kaufman, 2011, Leukemia & lymphoma.

A Vascular Targeted Pan PI-3 Kinase Inhibitor, SF1126 with Activity Against Multiple Myeloma In Vivo.

S. Lonial, P. De, D. Durden, 2006 .

A randomized clinical trial comparing granulocyte–colony‐stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation

C. Flowers, S. Lonial, J. Kaufman, 2011, Transfusion.

Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.

P. Tamayo, S. Fröhling, D. Brat, 2015, Molecular cell.

HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers

F. Khuri, S. Lonial, O. Abdel-Wahab, 2017, The Journal of Biological Chemistry.

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

S. Lonial, Jiangxia Liu, J. Kaufman, 2011, Blood.

Panobinostat for the treatment of multiple myeloma

S. Lonial, Minal Surati, K. Valla, 2015 .

Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin.

S. Lonial, E. Waller, D. Jaye, 2012, Experimental hematology.

Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea

S. Lonial, J. Kaufman, A. Nooka, 2014 .

Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses

S. Lonial, S. Knechtle, C. Joyner, 2023, bioRxiv.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma

P. Sonneveld, K. Anderson, S. Lonial, 2005 .

Epidermal Growth Factor Stimulates RSK2 Activation through Activation of the MEK/ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK2 at Tyr-529*

S. Lonial, T. Gu, A. Guo, 2008, Journal of Biological Chemistry.

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma

S. Lonial, T. Plesner, P. Voorhees, 2017, Clinical pharmacology and therapeutics.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

A. Jakubowiak, A. Krishnan, S. Lonial, 2008 .

Treatment of relapsed and refractory myeloma

S. Lonial, J. Kaufman, C. Gleason, 2009, Current hematologic malignancy reports.

Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes.

J. Armitage, S. Lonial, L. Bosserman, 2020, JCO Oncology Practice.

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

G. Morgan, H. Einsele, P. Sonneveld, 2022, Blood cancer discovery.

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY

S. Lonial, P. Richardson, N. Callander, 2022, HemaSphere.

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.

S. Jagannath, S. Lonial, D. Siegel, 2021, The Lancet. Haematology.

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

R. Dana, A. Jakubowiak, S. Lonial, 2021, Blood Cancer Journal.

TRAIL-Induced Apoptosis in Human Lung Cancer Cells Expression of Death Receptor 5 and Enhances The Farnesyltransferase Inhibitor R 115777 Upregulates the

F. Khuri, S. Lonial, Shi-Yong Sun, 2007 .

The Farnesyltransferase Inhibitor R 115777 Upregulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells

F. Khuri, S. Lonial, Shi-Yong Sun, 2007 .

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

K. Suryanarayan, M. Dimopoulos, S. Lonial, 2023, Blood Cancer Journal.

Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study.

K. Anderson, A. Krishnan, S. Lonial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients.

S. Lonial, P. Richardson, Shaji K. Kumar, 2021, Blood.

Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM).

Michael L. Wang, A. Hui, S. Lonial, 2012 .

Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study

A. Hui, A. Jakubowiak, S. Lonial, 2011 .

PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Bie M. P. Verbist, S. Lonial, T. Plesner, 2016 .

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

S. Jagannath, S. Lonial, D. Siegel, 2013 .

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

S. Jagannath, S. Lonial, T. Zimmerman, 2012 .

Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.

S. Lonial, Chuan He, M. L. Le Beau, 2021, Molecular cell.

Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.

A. Hui, S. Lonial, P. Richardson, 2012 .

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

S. Jagannath, S. Lonial, D. Siegel, 2021 .

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

H. Goldschmidt, S. Jagannath, S. Lonial, 2020 .

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

P. Sonneveld, S. Jagannath, S. Lonial, 2019, Blood.

ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).

M. Dimopoulos, S. Lonial, P. Richardson, 2012 .

Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients

S. Lonial, J. Kaufman, A. Nooka, 2013 .

Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).

M. Dimopoulos, K. Anderson, S. Jagannath, 2010 .

Precision medicine in multiple myeloma: are we there yet?

D. Auclair, S. Lonial, Shaji K. Kumar, 2019, Expert Review of Precision Medicine and Drug Development.

ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)--Identifying responders by subset analysis.

M. Dimopoulos, A. Palumbo, S. Lonial, 2016 .

Daratumumab: monoclonal antibody therapy to treat multiple myeloma.

S. Lonial, S. Scott, M. Ribeiro, 2016, Drugs of today.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

A. Jakubowiak, S. Lonial, J. Kaufman, 2019, Blood Cancer Journal.

Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma

S. Lonial, J. Laubach, P. Richardson, 2017, Pharmacological research.

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

H. Goldschmidt, P. Sonneveld, K. Anderson, 2005 .

Venetoclax ex vivo functional profiling predicts improved progression-free survival

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Blood Cancer Journal.

We need CD38 STAT-JAK.

S. Lonial, B. Barwick, 2020, Blood.

Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.

S. Jagannath, A. Jakubowiak, S. Lonial, 2013 .

Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2013 .

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

J. Keats, S. Lonial, A. Tron, 2018, Blood.

TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma.

S. Lonial, A. Nooka, L. Boise, 2017, Blood advances.

Multiple myeloma gammopathies A high-risk , Double-Hit , group of newly diagnosed myeloma identi fi ed by genomic analysis

H. Goldschmidt, G. Morgan, H. Einsele, 2018 .

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study

Winnie S. Liang, J. Carpten, S. Jewell, 2021, medRxiv.

Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.

G. Colditz, C. Haiman, D. Auclair, 2020, JCO oncology practice.

Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to anti-malarial agent dihydroartemisinin

F. Khuri, S. Lonial, T. Boggon, 2016, Oncogene.

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Sara W. Bird, Erinna F. Lee, Michael D. Kim, 2016 .

Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.

M. Dimopoulos, H. Einsele, S. Lonial, 2014 .

Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

S. Lonial, T. Facon, J. San-Miguel, 2010 .

FDA-approved novel agents to treat relapsed and refractory myeloma

S. Lonial, J. Kaufman, C. Gleason, 2009 .

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

S. Jagannath, S. Lonial, T. Zimmerman, 2011 .

FGFR3 Mutations Are an Adverse Prognostic Factor in Patients with t(4;14)(p16;q32) Multiple Myeloma: An Mmrf Commpass Analysis

D. Auclair, J. Keats, S. Lonial, 2017 .

HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS)

G. Colditz, C. Haiman, L. Kolonel, 2016 .

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

S. Jagannath, A. Jakubowiak, S. Lonial, 2012 .

CD86 regulates myeloma cell survival.

S. Lonial, B. Barwick, P. Neri, 2017, Blood advances.

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

S. Lonial, G. Vanhoof, T. Plesner, 2017 .

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

J. Fay, A. Krishnan, S. Lonial, 2017 .

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

J. Rossi, S. Jagannath, A. Jakubowiak, 2010 .

Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study

S. Jagannath, S. Lonial, R. Vij, 2010 .

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

S. Lonial, R. Vij, Zhengjia Chen, 2018, Blood.

Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.

A. Jakubowiak, S. Lonial, P. Moreau, 2018 .

An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.

S. Lonial, R. Vij, J. Laubach, 2017 .

Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma

S. Jagannath, S. Lonial, D. Siegel, 2016 .

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

S. Jagannath, S. Lonial, D. Siegel, 2012 .

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

S. Lonial, R. Orlowski, J. Kaufman, 2012 .

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

S. Jagannath, S. Lonial, P. Hari, 2012 .

Selinexor for the treatment of patients with previously treated multiple myeloma

S. Jagannath, S. Lonial, P. Richardson, 2021, Expert review of hematology.

A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

P. Sonneveld, S. Lonial, J. Zonder, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Deacetylase inhibitors: an advance in myeloma therapy?

H. Einsele, S. Lonial, J. Laubach, 2017, Expert review of hematology.

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

J. Shah, M. Dimopoulos, C. Hofmeister, 2020, Leukemia.

OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa

H. Goldschmidt, H. Einsele, S. Jagannath, 2021, Clinical Lymphoma Myeloma and Leukemia.

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

S. Lonial, S. Trudel, P. Richardson, 2022, Blood.

PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.

H. Einsele, S. Lonial, W. Jędrzejczak, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4.

K. Suryanarayan, H. Goldschmidt, G. Morgan, 2016 .

The current unmet medical needs in the treatment and management of multiple myeloma (MM)

S. Lonial, P. Richardson, A. Palumbo, 2015 .

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

M. Dimopoulos, A. Palumbo, S. Lonial, 2015 .

The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),

C. Flowers, S. Lonial, M. Behera, 2011 .

Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)

S. Lonial, P. Richardson, G. Warsi, 2011 .

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

C. Hofmeister, S. Lonial, M. Dhodapkar, 2018, Blood.

Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

S. Lonial, R. Orlowski, Honghui Zhou, 2015 .

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitor (PI) and Immunomodulatory Drug (IMiD) Treatment

S. Lonial, Honghui Zhou, H. Lokhorst, 2015 .

Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT)

S. Lonial, J. Laubach, P. Richardson, 2017 .

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

A. Krishnan, S. Lonial, Shaji K. Kumar, 2016 .

The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685)

S. Lonial, J. Miguel, R. Hájek, 2017 .

Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma

S. Lonial, R. Vij, K. Rajangam, 2012 .

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

S. Jagannath, S. Lonial, P. Richardson, 2013 .

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

C. Hofmeister, S. Lonial, J. Laubach, 2013 .

Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652

Lee, Duchen, Izzo, 2016 .

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

S. Jagannath, S. Lonial, R. Vij, 2009 .

New Targets and New Agents in High-Risk Multiple Myeloma.

S. Lonial, A. Nooka, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

M. Dimopoulos, H. Einsele, S. Lonial, 2017, British journal of haematology.

Maturation of Human Long-lived Plasma Cells Results in Resistance to Apoptosis by Transcriptional and Epigenetic Regulation

G. Gibson, S. Lonial, Christopher D. Scharer, 2021, bioRxiv.

A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma.

S. Lonial, S. Trudel, J. Kaufman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

H. Goldschmidt, P. Sonneveld, S. Lonial, 2004 .

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).

D. Esseltine, P. Wen, S. Lonial, 2004 .

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

C. Hofmeister, S. Lonial, J. Kaufman, 2022, Blood.

Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.

A. Krishnan, S. Lonial, P. Richardson, 2009 .

Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2009 .

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Lee-Jen Wei, M. Dimopoulos, S. Jagannath, 2020, EJHaem.

Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

S. Jagannath, S. Lonial, D. Siegel, 2020, American journal of hematology.

Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias

S. Lonial, K. Ramasamy, 2015 .

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

S. Lonial, P. Richardson, S. Horwitz, 2021, Blood.

Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma

S. Lonial, R. Harvey, Winifred Werther, 2014 .

P-279: Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial

S. Lonial, D. Siegel, P. Maciag, 2022, Clinical Lymphoma, Myeloma & Leukemia.

DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.

S. Lonial, S. Trudel, P. Richardson, 2020 .

Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study

J. Manola, S. Lonial, A. Dueck, 2018, Blood Cancer Journal.

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

S. Jagannath, S. Lonial, P. Richardson, 2015 .

Risk Stratification and Response Assessment in Multiple Myeloma and Waldenström's Macroglobulinemia

S. Lonial, S. Gentili, 2014 .

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

S. Jagannath, S. Lonial, D. Siegel, 2019, Blood.

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment

S. Lonial, D. Siegel, R. Harvey, 2013 .

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.

C. Hofmeister, S. Jagannath, S. Lonial, 2013 .

A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results.

A. Krishnan, S. Lonial, Shaji K. Kumar, 2016 .

Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials

S. Lonial, A. Dispenzieri, R. Kyle, 2008 .

Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)

S. Lonial, M. Golightly, T. Plesner, 2015 .

Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma

S. Lonial, J. Kaufman, A. Nooka, 2014 .

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

M. Dimopoulos, H. Einsele, S. Lonial, 2011 .

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

K. Suryanarayan, G. Morgan, M. Dimopoulos, 2021, Blood.

P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, S. Jagannath, S. Lonial, 2021, Clinical Lymphoma, Myeloma & Leukemia.

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

S. Lonial, P. Richardson, Shaji K. Kumar, 2020, Journal of Clinical Oncology.

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

S. Jagannath, S. Lonial, P. Richardson, 2014 .

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

M. Dimopoulos, S. Lonial, S. Trudel, 2021, Blood.

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

S. Lonial, T. Zimmerman, J. Kaufman, 2014 .

ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

M. Dimopoulos, A. Palumbo, S. Lonial, 2015 .

Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.

D. Esseltine, K. Anderson, S. Jagannath, 2010 .

Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM).

S. Lonial, R. Orlowski, J. Kaufman, 2010 .

Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

M. Dimopoulos, H. Einsele, S. Lonial, 2015 .

A268 Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses

S. Lonial, S. Knechtle, C. Joyner, 2023, Cell reports.

University of Southern Denmark High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

S. Lonial, G. Vanhoof, H. Ceulemans, 2019 .

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

A. Hui, S. Lonial, J. Laubach, 2014 .

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

C. Hofmeister, S. Lonial, M. Dhodapkar, 2018, Blood.

Up-Front Management of Multiple Myeloma

R. Fonseca, S. Lonial, N. Love, 2010 .

A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

Jason J. Z. Liao, S. Jagannath, S. Lonial, 2018 .

A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.

Jason J. Z. Liao, H. Goldschmidt, S. Jagannath, 2018 .

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

A. Jakubowiak, A. Krishnan, S. Lonial, 2020, Advances in Therapy.

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis

C. Hofmeister, S. Jagannath, S. Lonial, 2012 .

Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).

Lee-Jen Wei, M. Dimopoulos, S. Jagannath, 2019, Journal of Clinical Oncology.

Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma

S. Lonial, J. Kaufman, A. Nooka, 2013, Cancer biology & therapy.

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

Michael L. Wang, A. Jakubowiak, S. Lonial, 2007, Clinical advances in hematology & oncology : H&O.

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

S. Lonial, A. Nooka, C. Gleason, 2013 .

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.

S. Jagannath, A. Jakubowiak, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

J. Fay, A. Krishnan, S. Lonial, 2017, Blood.

Correlation Between Somatic Mutation Burden, Neoantigen Load and Progression Free Survival in Multiple Myeloma: Analysis of MMRF CoMMpass Study

Y. Asmann, D. Auclair, J. Keats, 2016 .

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study

S. Lonial, A. Oriol, P. Moreau, 2017 .

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

S. Lonial, N. Munshi, J. Laubach, 2023, Haematologica.

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

S. Lonial, R. Orlowski, J. Kaufman, 2011 .

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

D. Auclair, J. Keats, C. Hofmeister, 2019, Nature Communications.

Epidermal Growth Factor Stimulates RSK 2 Activation through Activation of the MEK / ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK 2 at Tyr-529

S. Lonial, T. Gu, A. Guo, 2022 .

A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2023, Journal of Clinical Oncology.

A Review of Cancer Risk Prediction Models with Genetic Variants

Zhaohui S. Qin, S. Lonial, C. Moreno, 2014, Cancer informatics.

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

H. Einsele, S. Lonial, A. Lesokhin, 2023, Blood cancer journal.

KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

S. Jagannath, S. Lonial, N. Raje, 2021, Blood.

Interim Analysis of the MMRF CoMMpass Study: Comprehensive Characterization of Multiple Myeloma Patients at Diagnosis Reveals Distinct Molecular Subtypes and Clinical Outcomes

Winnie S. Liang, J. Carpten, J. Fay, 2015 .

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

C. Hofmeister, S. Lonial, M. Dhodapkar, 2023, The Journal of clinical investigation.

CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

S. Lonial, J. Miguel, P. Richardson, 2017 .

CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

S. Lonial, J. Miguel, P. Richardson, 2017 .

Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).

S. Lonial, S. Trudel, N. Callander, 2020 .

DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.

S. Lonial, S. Trudel, P. Richardson, 2020 .

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Blood.

Phase I/II trial of pralatrexate in patients with chemotherapy-resistant precursor and peripheral T-cell lymphomas

J. Armitage, S. Lonial, L. Shivakumar, 2007 .

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

S. Lonial, P. Richardson, S. Coutre, 2012 .

Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

S. Lonial, J. Kaufman, A. Nooka, 2017 .

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

A. Jakubowiak, S. Lonial, P. Thulasi, 2020 .

Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies

S. Lonial, Zhengjia Chen, J. Kaufman, 2019, Cancer.

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

A. Jakubowiak, S. Lonial, Jeffrey N. Martin, 2007 .

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

B. Barlogie, S. Jagannath, S. Lonial, 2006 .

Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM).

S. Lonial, P. Richardson, C. Mitsiades, 2005, Journal of Clinical Oncology.

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

M. Kaminski, D. Esseltine, K. Griffith, 2011, Blood.

Guidelines for the use and interpretation of assays for monitoring autophagy

Robert Clarke, Hong Jiang, Hiroyuki Ishida, 2012 .

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

H. Goldschmidt, A. Palumbo, H. Johnsen, 2014, The Lancet. Oncology.

Review of peripheral neuropathy in plasma cell disorders

S. Lonial, Jeannine Silberman, 2008, Hematological oncology.

Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.

D. Brat, R. Deberardinis, F. Khuri, 2014, Molecular cell.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019, JCI insight.

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.

S. Lonial, Shi-Yong Sun, J. Kaufman, 2011, Blood.

Guidelines for the use and interpretation of assays for monitoring autophage

T. P. Neufeld, Thomas J. Begley, H. Coller, 2012 .

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype

G. Sica, Melissa Gilbert-Ross, F. Khuri, 2022 .

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

B. Barlogie, J. Shaughnessy, R. Fonseca, 2010, Mayo Clinic proceedings.

Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation*

F. Khuri, S. Lonial, Shi-Yong Sun, 2010, The Journal of Biological Chemistry.

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

S. Lonial, S. Bates, S. Whittaker, 2009 .

Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.

S. Lonial, W. Jędrzejczak, P. Richardson, 2014 .

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).

C. Hofmeister, S. Lonial, D. Siegel, 2013 .

Phase III Trial: Bortezomib/Thalidomide/Dexamethasone Versus Thalidomide/Dexamethasone Alone: Efficacy

S. Jagannath, S. Lonial, S. Stilgenbauer, 2009 .

Multiple myeloma immunoglobulin λ translocations portend poor prognosis

D. Auclair, J. Keats, S. Lonial, 2018, bioRxiv.

Management of treatment-emergent peripheral neuropathy in multiple myeloma

P. Wen, G. Morgan, M. Dimopoulos, 2012, Leukemia.

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2015, British journal of haematology.

Impaired SARS-CoV-2 variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections.

A. Sette, C. Hofmeister, S. Lonial, 2022, Blood cancer discovery.

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

H. Goldschmidt, H. Einsele, A. Palumbo, 2016, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

R. Neuwirth, H. Goldschmidt, P. Sonneveld, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Michael L. Wang, A. Hui, A. Jakubowiak, 2014, Blood.

Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma.

A. Krishnan, S. Lonial, A. Chari, 2023, Clinical lymphoma, myeloma & leukemia.

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.

M. Dimopoulos, S. Lonial, P. Richardson, 2022, Clinical lymphoma, myeloma & leukemia.

Regulation of alloimmune responses by dendritic cell subsets.

S. Lonial, E. Waller, M. Arellano, 2008, Experimental hematology.

A. Krishnan, S. Lonial, Shaji K. Kumar, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Biologics: Targets and Therapy Dovepress Emerging Treatments in Castleman Disease – a Critical Appraisal of Siltuximab

S. Lonial, J. Koff, 2022 .

The Multiple Myeloma Research Foundation (MMRF) CoMMpassSM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles, Immunophenotypes and Clinical Outcomes

J. Carpten, S. Jewell, J. Keats, 2012 .

Bayesian Network Models of Multiple Myeloma: Drivers of High Risk and Durable Response

B. Hayete, D. Auclair, J. Keats, 2016 .

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis.

A. Krishnan, S. Lonial, R. Vij, 2011, Blood.

Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070

S. Lonial, J. Chen, S. Dong, 2008, Leukemia.

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.

S. Lonial, S. Trudel, P. Richardson, 2023, The New England journal of medicine.